Targeting HER2-positive breast cancer: advances and future directions
SM Swain, M Shastry, E Hamilton - Nature reviews Drug discovery, 2023 - nature.com
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
L Chen, W Hong, W Ren, T Xu, Z Qian… - Signal transduction and …, 2021 - nature.com
Over the past decades, great interest has been given to biomimetic nanoparticles (BNPs)
since the rise of targeted drug delivery systems and biomimetic nanotechnology. Biological …
since the rise of targeted drug delivery systems and biomimetic nanotechnology. Biological …
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
J Liu, M Fu, M Wang, D Wan, Y Wei, X Wei - Journal of Hematology & …, 2022 - Springer
Research on tumor immunotherapy has made tremendous progress in the past decades,
with numerous studies entering the clinical evaluation. The cancer vaccine is considered a …
with numerous studies entering the clinical evaluation. The cancer vaccine is considered a …
Emerging targeted therapies for HER2-positive breast cancer
MF Mercogliano, S Bruni, FL Mauro, R Schillaci - Cancers, 2023 - mdpi.com
Simple Summary HER2-positive breast cancer (BC), which accounts for~ 20% of BC, is one
of the more aggressive and has the worst overall survival rate among them. These patients …
of the more aggressive and has the worst overall survival rate among them. These patients …
Rise of the RNA machines–self-amplification in mRNA vaccine design
JDG Comes, GP Pijlman, TAH Hick - Trends in Biotechnology, 2023 - cell.com
Abstract mRNA vaccines have won the race for early COVID-19 vaccine approval, yet
improvements are necessary to retain this leading role in combating infectious diseases. A …
improvements are necessary to retain this leading role in combating infectious diseases. A …
Vaccine therapies for cancer: then and now
MA Morse, WR Gwin III, DA Mitchell - Targeted oncology, 2021 - Springer
There are strong biologic and preclinical rationales for the development of therapeutic
cancer vaccines; however, the clinical translation of this treatment strategy has been …
cancer vaccines; however, the clinical translation of this treatment strategy has been …
Clinical trials of self-replicating RNA-based cancer vaccines
Therapeutic cancer vaccines, designed to activate immune effectors against tumor antigens,
utilize a number of different platforms for antigen delivery. Among these are messenger …
utilize a number of different platforms for antigen delivery. Among these are messenger …
Self-replicating RNA viruses for vaccine development against infectious diseases and cancer
K Lundstrom - Vaccines, 2021 - mdpi.com
Alphaviruses, flaviviruses, measles viruses and rhabdoviruses are enveloped single-
stranded RNA viruses, which have been engineered for recombinant protein expression and …
stranded RNA viruses, which have been engineered for recombinant protein expression and …
[HTML][HTML] PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy
Abstract “Foreignization” of tumor cells via delivery of a non-self foreign antigen (Ag) into
tumors is an appealing strategy to initiate anti-tumor immunity that can facilitate tumor …
tumors is an appealing strategy to initiate anti-tumor immunity that can facilitate tumor …
Peptide-based vaccines in clinical phases and new potential therapeutic targets as a new approach for breast cancer: a review
ML Nicolas-Morales, A Luisa-Sanjuan… - Vaccines, 2022 - mdpi.com
Breast cancer is the leading cause of death in women from 20 to 59 years old. The
conventional treatment includes surgery, chemotherapy, hormonal therapy, and …
conventional treatment includes surgery, chemotherapy, hormonal therapy, and …